Treatment of Hepatitis B in Decompensated Liver Cirrhosis
Author Information
Author(s): Richard Guan, Hock Foong Lui
Primary Institution: Mount Elizabeth Hospital and Medical Centre, Singapore
Hypothesis
Can antiviral agents improve outcomes in patients with decompensated liver cirrhosis due to hepatitis B?
Conclusion
Antiviral therapy can improve or stabilize liver disease in patients with decompensated HBV cirrhosis.
Supporting Evidence
- Chronic hepatitis B infection can lead to serious liver complications.
- Antiviral agents like lamivudine, entecavir, and tenofovir are effective in managing decompensated HBV cirrhosis.
- Patients with decompensated cirrhosis have a poor prognosis, with a 5-year survival rate of only 14%.
- Early treatment with antiviral therapy can stabilize liver disease and improve outcomes.
Takeaway
This study shows that medicines can help people with serious liver problems caused by hepatitis B, making them feel better and live longer.
Methodology
The article reviews the epidemiology, disease progression, and medical management of patients with decompensated HBV cirrhosis, focusing on antiviral agents.
Potential Biases
Potential biases due to non-randomized studies and historical controls.
Limitations
The study lacks controlled trials and has varying inclusion criteria across studies.
Participant Demographics
The study includes a diverse population, with a significant number of Asian participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website